1
|
Yuan Y, Yu L, Zhuang X, Wen D, He J, Hong J, Xie J, Ling S, Du X, Chen W, Wang X. Drosophila models used to simulate human ATP1A1 gene mutations that cause Charcot-Marie-Tooth type 2 disease and refractory seizures. Neural Regen Res 2025; 20:265-276. [PMID: 38767491 PMCID: PMC11246156 DOI: 10.4103/1673-5374.391302] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2023] [Revised: 09/21/2023] [Accepted: 11/06/2023] [Indexed: 05/22/2024] Open
Abstract
JOURNAL/nrgr/04.03/01300535-202501000-00034/figure1/v/2024-05-14T021156Z/r/image-tiff Certain amino acids changes in the human Na+/K+-ATPase pump, ATPase Na+/K+ transporting subunit alpha 1 (ATP1A1), cause Charcot-Marie-Tooth disease type 2 (CMT2) disease and refractory seizures. To develop in vivo models to study the role of Na+/K+-ATPase in these diseases, we modified the Drosophila gene homolog, Atpα, to mimic the human ATP1A1 gene mutations that cause CMT2. Mutations located within the helical linker region of human ATP1A1 (I592T, A597T, P600T, and D601F) were simultaneously introduced into endogenous DrosophilaAtpα by CRISPR/Cas9-mediated genome editing, generating the AtpαTTTF model. In addition, the same strategy was used to generate the corresponding single point mutations in flies (AtpαI571T, AtpαA576T, AtpαP579T, and AtpαD580F). Moreover, a deletion mutation (Atpαmut) that causes premature termination of translation was generated as a positive control. Of these alleles, we found two that could be maintained as homozygotes (AtpαI571T and AtpαP579T). Three alleles (AtpαA576T, AtpαP579 and AtpαD580F) can form heterozygotes with the Atpαmut allele. We found that the Atpα allele carrying these CMT2-associated mutations showed differential phenotypes in Drosophila. Flies heterozygous for AtpαTTTF mutations have motor performance defects, a reduced lifespan, seizures, and an abnormal neuronal morphology. These Drosophila models will provide a new platform for studying the function and regulation of the sodium-potassium pump.
Collapse
Affiliation(s)
- Yao Yuan
- Institute of Life Sciences, College of Biological Science and Engineering, Fuzhou University, Fuzhou, Fujian Province, China
| | - Lingqi Yu
- Institute of Life Sciences, College of Biological Science and Engineering, Fuzhou University, Fuzhou, Fujian Province, China
| | - Xudong Zhuang
- NHC Key Laboratory of Technical Evaluation of Fertility Regulation for Non-human Primate (Fujian Maternity and Child Health Hospital), Fuzhou, Fujian Province, China
- Medical Research Center, Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, Fujian Province, China
| | - Dongjing Wen
- Institute of Life Sciences, College of Biological Science and Engineering, Fuzhou University, Fuzhou, Fujian Province, China
| | - Jin He
- Department of Neurology and Institute of Neurology of The First Affiliated Hospital, Institute of Neuroscience, and Fujian Key Laboratory of Molecular Neurology, Fujian Medical University, Fuzhou, Fujian Province, China
| | - Jingmei Hong
- Department of Neurology and Institute of Neurology of The First Affiliated Hospital, Institute of Neuroscience, and Fujian Key Laboratory of Molecular Neurology, Fujian Medical University, Fuzhou, Fujian Province, China
| | - Jiayu Xie
- Institute of Life Sciences, College of Biological Science and Engineering, Fuzhou University, Fuzhou, Fujian Province, China
| | - Shengan Ling
- Institute of Life Sciences, College of Biological Science and Engineering, Fuzhou University, Fuzhou, Fujian Province, China
| | - Xiaoyue Du
- Institute of Life Sciences, College of Biological Science and Engineering, Fuzhou University, Fuzhou, Fujian Province, China
| | - Wenfeng Chen
- Institute of Life Sciences, College of Biological Science and Engineering, Fuzhou University, Fuzhou, Fujian Province, China
| | - Xinrui Wang
- NHC Key Laboratory of Technical Evaluation of Fertility Regulation for Non-human Primate (Fujian Maternity and Child Health Hospital), Fuzhou, Fujian Province, China
- Medical Research Center, Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, Fujian Province, China
| |
Collapse
|
2
|
Dohrn MF, Bademci G, Rebelo AP, Jeanne M, Borja NA, Beijer D, Danzi MC, Bivona SA, Gueguen P, Zafeer MF, Tekin M, Züchner S. Recurrent ATP1A1 variant Gly903Arg causes developmental delay, intellectual disability, and autism. Ann Clin Transl Neurol 2024; 11:1075-1079. [PMID: 38504481 PMCID: PMC11021672 DOI: 10.1002/acn3.51963] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2023] [Revised: 11/15/2023] [Accepted: 11/18/2023] [Indexed: 03/21/2024] Open
Abstract
ATP1A1 encodes a sodium-potassium ATPase that has been linked to several neurological diseases. Using exome and genome sequencing, we identified the heterozygous ATP1A1 variant NM_000701.8: c.2707G>A;p.(Gly903Arg) in two unrelated children presenting with delayed motor and speech development and autism. While absent in controls, the variant occurred de novo in one proband and co-segregated in two affected half-siblings, with mosaicism in the healthy mother. Using a specific ouabain resistance assay in mutant transfected HEK cells, we found significantly reduced cell viability. Demonstrating loss of ATPase function, we conclude that this novel variant is pathogenic, expanding the phenotype spectrum of ATP1A1.
Collapse
Affiliation(s)
- Maike F. Dohrn
- Dr. John T. Macdonald Foundation, Department of Human GeneticsJohn P. Hussman Institute for Human Genomics, University of Miami, Miller School of MedicineMiamiFloridaUSA
- Department of NeurologyMedical Faculty of the RWTH Aachen UniversityAachenGermany
| | - Guney Bademci
- Dr. John T. Macdonald Foundation, Department of Human GeneticsJohn P. Hussman Institute for Human Genomics, University of Miami, Miller School of MedicineMiamiFloridaUSA
| | - Adriana P. Rebelo
- Dr. John T. Macdonald Foundation, Department of Human GeneticsJohn P. Hussman Institute for Human Genomics, University of Miami, Miller School of MedicineMiamiFloridaUSA
| | - Médéric Jeanne
- Service de Génétique Médicale, CHRU de ToursToursFrance
- UMR 1253, iBrain, Université de Tours, INSERMToursFrance
- Laboratoire de Biologie Médicale Multi‐Sites SeqOIA (laboratoire‐seqoia.fr/)ParisFrance
| | - Nicholas A. Borja
- Dr. John T. Macdonald Foundation, Department of Human GeneticsJohn P. Hussman Institute for Human Genomics, University of Miami, Miller School of MedicineMiamiFloridaUSA
| | - Danique Beijer
- Dr. John T. Macdonald Foundation, Department of Human GeneticsJohn P. Hussman Institute for Human Genomics, University of Miami, Miller School of MedicineMiamiFloridaUSA
| | - Matt C. Danzi
- Dr. John T. Macdonald Foundation, Department of Human GeneticsJohn P. Hussman Institute for Human Genomics, University of Miami, Miller School of MedicineMiamiFloridaUSA
| | - Stephanie A. Bivona
- Dr. John T. Macdonald Foundation, Department of Human GeneticsJohn P. Hussman Institute for Human Genomics, University of Miami, Miller School of MedicineMiamiFloridaUSA
| | - Paul Gueguen
- Service de Génétique Médicale, CHRU de ToursToursFrance
| | - Mohammad F. Zafeer
- Dr. John T. Macdonald Foundation, Department of Human GeneticsJohn P. Hussman Institute for Human Genomics, University of Miami, Miller School of MedicineMiamiFloridaUSA
| | - Mustafa Tekin
- Dr. John T. Macdonald Foundation, Department of Human GeneticsJohn P. Hussman Institute for Human Genomics, University of Miami, Miller School of MedicineMiamiFloridaUSA
| | - Stephan Züchner
- Dr. John T. Macdonald Foundation, Department of Human GeneticsJohn P. Hussman Institute for Human Genomics, University of Miami, Miller School of MedicineMiamiFloridaUSA
| |
Collapse
|
3
|
Spontarelli K, Young VC, Sweazey R, Padro A, Lee J, Bueso T, Hernandez RM, Kim J, Katz A, Rossignol F, Turner C, Wilczewski CM, Maxwell GL, Holmgren M, Bailoo JD, Yano ST, Artigas P. ATP1A1-linked diseases require a malfunctioning protein product from one allele. BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR CELL RESEARCH 2024; 1871:119572. [PMID: 37659504 DOI: 10.1016/j.bbamcr.2023.119572] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/28/2023] [Revised: 07/06/2023] [Accepted: 08/22/2023] [Indexed: 09/04/2023]
Abstract
Heterozygous germline variants in ATP1A1, the gene encoding the α1 subunit of the Na+/K+-ATPase (NKA), have been linked to diseases including primary hyperaldosteronism and the peripheral neuropathy Charcot-Marie-Tooth disease (CMT). ATP1A1 variants that cause CMT induce loss-of-function of NKA. This heterodimeric (αβ) enzyme hydrolyzes ATP to establish transmembrane electrochemical gradients of Na+ and K+ that are essential for electrical signaling and cell survival. Of the 4 catalytic subunit isoforms, α1 is ubiquitously expressed and is the predominant paralog in peripheral axons. Human population sequencing datasets indicate strong negative selection against both missense and protein-null ATP1A1 variants. To test whether haploinsufficiency generated by heterozygous protein-null alleles are sufficient to cause disease, we tested the neuromuscular characteristics of heterozygous Atp1a1+/- knockout mice and their wildtype littermates, while also evaluating if exercise increased CMT penetrance. We found that Atp1a1+/- mice were phenotypically normal up to 18 months of age. Consistent with the observations in mice, we report clinical phenotyping of a healthy adult human who lacks any clinical features of known ATP1A1-related diseases despite carrying a plasma-membrane protein-null early truncation variant, p.Y148*. Taken together, these results suggest that a malfunctioning gene product is required for disease induction by ATP1A1 variants and that if any pathology is associated with protein-null variants, they may display low penetrance or high age of onset.
Collapse
Affiliation(s)
- Kerri Spontarelli
- Department of Cell Physiology and Molecular Biophysics, Center for Membrane Protein Research, Texas Tech University Health Sciences Center, Lubbock, TX, USA
| | - Victoria C Young
- Department of Cell Physiology and Molecular Biophysics, Center for Membrane Protein Research, Texas Tech University Health Sciences Center, Lubbock, TX, USA
| | - Ryan Sweazey
- Department of Cell Physiology and Molecular Biophysics, Center for Membrane Protein Research, Texas Tech University Health Sciences Center, Lubbock, TX, USA
| | - Alexandria Padro
- Department of Cell Physiology and Molecular Biophysics, Center for Membrane Protein Research, Texas Tech University Health Sciences Center, Lubbock, TX, USA
| | - Jeannie Lee
- Department of Neurology, Texas Tech University Health Sciences Center, Lubbock, TX, USA
| | - Tulio Bueso
- Department of Neurology, Texas Tech University Health Sciences Center, Lubbock, TX, USA
| | - Roberto M Hernandez
- Department of Neurology, Texas Tech University Health Sciences Center, Lubbock, TX, USA
| | - Jongyeol Kim
- Department of Neurology, Texas Tech University Health Sciences Center, Lubbock, TX, USA
| | - Alexander Katz
- NIH Reverse Phenotyping Core, National Institutes of Health, Bethesda, MD, USA; National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
| | - Francis Rossignol
- National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
| | - Clesson Turner
- NIH Reverse Phenotyping Core, National Institutes of Health, Bethesda, MD, USA; National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
| | - Caralynn M Wilczewski
- NIH Reverse Phenotyping Core, National Institutes of Health, Bethesda, MD, USA; National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
| | - George L Maxwell
- Women's Health Integrated Research Center, Inova Health System, Falls Church, VA, USA
| | - Miguel Holmgren
- Molecular Neurophysiology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA
| | - Jeremy D Bailoo
- Department of Cell Biology and Biochemistry, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
| | - Sho T Yano
- National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA; Molecular Neurophysiology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA; Current address: Section of Pediatric Neurology, Department of Pediatrics, University of Chicago, Chicago, IL, USA.
| | - Pablo Artigas
- Department of Cell Physiology and Molecular Biophysics, Center for Membrane Protein Research, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
| |
Collapse
|
4
|
Spontarelli K, Young VC, Sweazey R, Padro A, Lee J, Bueso T, Hernandez RM, Kim J, Katz A, Rossignol F, Turner C, Wilczewski CM, Maxwell GL, Holmgren M, Bailoo JD, Yano ST, Artigas P. ATP1A1 -linked diseases require a malfunctioning protein product from one allele. BIORXIV : THE PREPRINT SERVER FOR BIOLOGY 2023:2023.03.05.531165. [PMID: 37090550 PMCID: PMC10120656 DOI: 10.1101/2023.03.05.531165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/29/2023]
Abstract
Heterozygous germline variants in ATP1A1 , the gene encoding the α1 subunit of the Na + /K + -ATPase (NKA), have been linked to diseases including primary hyperaldosteronism and the peripheral neuropathy Charcot-Marie-Tooth disease (CMT). ATP1A1 variants that cause CMT induce loss-of-function of NKA. This heterodimeric (αβ) enzyme hydrolyzes ATP to establish transmembrane electrochemical gradients of Na + and K + that are essential for electrical signaling and cell survival. Of the 4 catalytic subunit isoforms, α1 is ubiquitously expressed and is the predominant paralog in peripheral axons. Human population sequencing datasets indicate strong negative selection against both missense and protein-null ATP1A1 variants. To test whether haploinsufficiency generated by heterozygous protein-null alleles are sufficient to cause disease, we tested the neuromuscular characteristics of heterozygous Atp1a1 +/- knockout mice and their wildtype littermates, while also evaluating if exercise increased CMT penetrance. We found that Atp1a1 +/- mice were phenotypically normal up to 18 months of age. Consistent with the observations in mice, we report clinical phenotyping of a healthy adult human who lacks any clinical features of known ATP1A1 -related diseases despite carrying a protein-null early truncation variant, p.Y148*. Taken together, these results suggest that a malfunctioning gene product is required for disease induction by ATP1A1 variants and that if any pathology is associated with protein-null variants, they may display low penetrance or high age of onset.
Collapse
|
5
|
Cinarli Yuksel F, Nicolaou P, Spontarelli K, Dohrn MF, Rebelo AP, Koutsou P, Georghiou A, Artigas P, Züchner SL, Kleopa KA, Christodoulou K. The phenotypic spectrum of pathogenic ATP1A1 variants expands: the novel p.P600R substitution causes demyelinating Charcot-Marie-Tooth disease. J Neurol 2023; 270:2576-2590. [PMID: 36738336 PMCID: PMC10130110 DOI: 10.1007/s00415-023-11581-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2022] [Revised: 01/17/2023] [Accepted: 01/18/2023] [Indexed: 02/05/2023]
Abstract
BACKGROUND Charcot-Marie-Tooth disease (CMT) is a genetically and clinically heterogeneous group of inherited neuropathies. Monoallelic pathogenic variants in ATP1A1 were associated with axonal and intermediate CMT. ATP1A1 encodes for the catalytic α1 subunit of the Na+/ K+ ATPase. Besides neuropathy, other associated phenotypes are spastic paraplegia, intellectual disability, and renal hypomagnesemia. We hereby report the first demyelinating CMT case due to a novel ATP1A1 variant. METHODS Whole-exome sequencing on the patient's genomic DNA and Sanger sequencing to validate and confirm the segregation of the identified p.P600R ATP1A1 variation were performed. To evaluate functional effects, blood-derived mRNA and protein levels of ATP1A1 and the auxiliary β1 subunit encoded by ATP1B1 were investigated. The ouabain-survival assay was performed in transfected HEK cells to assess cell viability, and two-electrode voltage clamp studies were performed in Xenopus oocytes. RESULTS The variant was absent in the local and global control datasets, falls within a highly conserved protein position, and is in a missense-constrained region. The expression levels of ATP1A1 and ATP1B1 were significantly reduced in the patient compared to healthy controls. Electrophysiology indicated that ATP1A1p.P600R injected Xenopus oocytes have reduced Na+/ K+ ATPase function. Moreover, HEK cells transfected with a construct encoding ATP1A1p.P600R harbouring variants that confers ouabain insensitivity displayed a significant decrease in cell viability after ouabain treatment compared to the wild type, further supporting the pathogenicity of this variant. CONCLUSION Our results further confirm the causative role of ATP1A1 in peripheral neuropathy and broaden the mutational and phenotypic spectrum of ATP1A1-associated CMT.
Collapse
Affiliation(s)
- Feride Cinarli Yuksel
- Neurogenetics Department, The Cyprus Institute of Neurology and Genetics, 1683, Nicosia, Cyprus
| | - Paschalis Nicolaou
- Neurogenetics Department, The Cyprus Institute of Neurology and Genetics, 1683, Nicosia, Cyprus
| | - Kerri Spontarelli
- Department of Cell Physiology and Molecular Biophysics, Center for Membrane Protein Research, Texas Tech University Health Sciences Center, Lubbock, TX, USA
| | - Maike F Dohrn
- Dr. John T. Macdonald Foundation, Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami, Miller School of Medicine, Miami, FL, USA.,Department of Neurology, RWTH Aachen University Hospital, Aachen, Germany
| | - Adriana P Rebelo
- Dr. John T. Macdonald Foundation, Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami, Miller School of Medicine, Miami, FL, USA
| | - Pantelitsa Koutsou
- Neurogenetics Department, The Cyprus Institute of Neurology and Genetics, 1683, Nicosia, Cyprus
| | - Anthi Georghiou
- Neurogenetics Department, The Cyprus Institute of Neurology and Genetics, 1683, Nicosia, Cyprus
| | - Pablo Artigas
- Department of Cell Physiology and Molecular Biophysics, Center for Membrane Protein Research, Texas Tech University Health Sciences Center, Lubbock, TX, USA
| | - Stephan L Züchner
- Dr. John T. Macdonald Foundation, Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami, Miller School of Medicine, Miami, FL, USA
| | - Kleopas A Kleopa
- Neuroscience Department and the Centre for Neuromuscular Disorders, The Cyprus Institute of Neurology and Genetics, 1683, Nicosia, Cyprus
| | - Kyproula Christodoulou
- Neurogenetics Department, The Cyprus Institute of Neurology and Genetics, 1683, Nicosia, Cyprus.
| |
Collapse
|
6
|
Dohrn MF, Rebelo AP, Srivastava S, Cappuccio G, Smigiel R, Malhotra A, Basel D, van de Laar I, Neuteboom RF, Aarts-Tesselaar C, Mahida S, Brunetti-Pierri N, Taft RJ, Züchner S. De Novo ATP1A1 Variants in an Early-Onset Complex Neurodevelopmental Syndrome. Neurology 2022; 98:440-445. [PMID: 35110381 PMCID: PMC8935442 DOI: 10.1212/wnl.0000000000013276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2021] [Accepted: 12/17/2021] [Indexed: 11/15/2022] Open
Abstract
ATP1A1 encodes the α1 subunit of the sodium-potassium ATPase, an electrogenic cation pump highly expressed in the nervous system. Pathogenic variants in other subunits of the same ATPase, encoded by ATP1A2 or ATP1A3, are associated with syndromes such as hemiplegic migraine, dystonia, or cerebellar ataxia. Worldwide, only 16 families have been reported carrying pathogenic ATP1A1 variants to date. Associated phenotypes are axonal neuropathies, spastic paraplegia, and hypomagnesemia with seizures and intellectual disability. By whole exome or genome sequencing, we identified 5 heterozygous ATP1A1 variants, c.674A>G;p.Gln225Arg, c.1003G>T;p.Gly335Cys, c.1526G>A;p.Gly509Asp, c.2152G>A;p.Gly718Ser, and c.2768T>A;p.Phe923Tyr, in 5 unrelated children with intellectual disability, spasticity, and peripheral, motor predominant neuropathy. Additional features were sensory loss, sleep disturbances, and seizures. All variants occurred de novo and are absent from control populations (MAF GnomAD = 0). Affecting conserved amino acid residues and constrained regions, all variants have high pathogenicity in silico prediction scores. In HEK cells transfected with ouabain-insensitive ATP1A1 constructs, cell viability was significantly decreased in mutants after 72h treatment with the ATPase inhibitor ouabain, demonstrating loss of ATPase function. Replicating the haploinsufficiency mechanism of disease with a gene-specific assay provides pathogenicity information and increases certainty in variant interpretation. This study further expands the genotype-phenotype spectrum of ATP1A1.
Collapse
Affiliation(s)
- Maike F Dohrn
- From the Dr. John T. Macdonald Foundation (M.F.D., A.P.R., S.Z.), Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami, Miller School of Medicine, FL; Department of Neurology (M.F.D.), Medical Faculty, RWTH Aachen University Hospital, Aachen, Germany; Department of Neurology (S.S., S.M.), Boston Children's Hospital, Harvard Medical School, MA; Department of Translational Medicine (G.C., N.B.-P.), Federico II University; Telethon Institute of Genetics and Medicine (G.C., N.B.-P.), Pozzuoli, Naples, Italy; Department of Pediatrics and Rare Disorders (R.S.), Wroclaw Medical University, Poland; Illumina Inc (A.M., R.T.), San Diego, CA; Division of Pediatric Genetics (D.B.), Department of Genetics, Medical College of Wisconsin, Milwaukee; Department of Clinical Genetics (I.L.), Erasmus MC, University Medical Center Rotterdam; Department of Neurology (R.F.N.), Eramus MC, Medical Center Rotterdam; and Amphia Hospital (C.A.-T.), Breda, the Netherlands
| | - Adriana P Rebelo
- From the Dr. John T. Macdonald Foundation (M.F.D., A.P.R., S.Z.), Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami, Miller School of Medicine, FL; Department of Neurology (M.F.D.), Medical Faculty, RWTH Aachen University Hospital, Aachen, Germany; Department of Neurology (S.S., S.M.), Boston Children's Hospital, Harvard Medical School, MA; Department of Translational Medicine (G.C., N.B.-P.), Federico II University; Telethon Institute of Genetics and Medicine (G.C., N.B.-P.), Pozzuoli, Naples, Italy; Department of Pediatrics and Rare Disorders (R.S.), Wroclaw Medical University, Poland; Illumina Inc (A.M., R.T.), San Diego, CA; Division of Pediatric Genetics (D.B.), Department of Genetics, Medical College of Wisconsin, Milwaukee; Department of Clinical Genetics (I.L.), Erasmus MC, University Medical Center Rotterdam; Department of Neurology (R.F.N.), Eramus MC, Medical Center Rotterdam; and Amphia Hospital (C.A.-T.), Breda, the Netherlands
| | - Siddharth Srivastava
- From the Dr. John T. Macdonald Foundation (M.F.D., A.P.R., S.Z.), Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami, Miller School of Medicine, FL; Department of Neurology (M.F.D.), Medical Faculty, RWTH Aachen University Hospital, Aachen, Germany; Department of Neurology (S.S., S.M.), Boston Children's Hospital, Harvard Medical School, MA; Department of Translational Medicine (G.C., N.B.-P.), Federico II University; Telethon Institute of Genetics and Medicine (G.C., N.B.-P.), Pozzuoli, Naples, Italy; Department of Pediatrics and Rare Disorders (R.S.), Wroclaw Medical University, Poland; Illumina Inc (A.M., R.T.), San Diego, CA; Division of Pediatric Genetics (D.B.), Department of Genetics, Medical College of Wisconsin, Milwaukee; Department of Clinical Genetics (I.L.), Erasmus MC, University Medical Center Rotterdam; Department of Neurology (R.F.N.), Eramus MC, Medical Center Rotterdam; and Amphia Hospital (C.A.-T.), Breda, the Netherlands
| | - Gerarda Cappuccio
- From the Dr. John T. Macdonald Foundation (M.F.D., A.P.R., S.Z.), Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami, Miller School of Medicine, FL; Department of Neurology (M.F.D.), Medical Faculty, RWTH Aachen University Hospital, Aachen, Germany; Department of Neurology (S.S., S.M.), Boston Children's Hospital, Harvard Medical School, MA; Department of Translational Medicine (G.C., N.B.-P.), Federico II University; Telethon Institute of Genetics and Medicine (G.C., N.B.-P.), Pozzuoli, Naples, Italy; Department of Pediatrics and Rare Disorders (R.S.), Wroclaw Medical University, Poland; Illumina Inc (A.M., R.T.), San Diego, CA; Division of Pediatric Genetics (D.B.), Department of Genetics, Medical College of Wisconsin, Milwaukee; Department of Clinical Genetics (I.L.), Erasmus MC, University Medical Center Rotterdam; Department of Neurology (R.F.N.), Eramus MC, Medical Center Rotterdam; and Amphia Hospital (C.A.-T.), Breda, the Netherlands
| | - Robert Smigiel
- From the Dr. John T. Macdonald Foundation (M.F.D., A.P.R., S.Z.), Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami, Miller School of Medicine, FL; Department of Neurology (M.F.D.), Medical Faculty, RWTH Aachen University Hospital, Aachen, Germany; Department of Neurology (S.S., S.M.), Boston Children's Hospital, Harvard Medical School, MA; Department of Translational Medicine (G.C., N.B.-P.), Federico II University; Telethon Institute of Genetics and Medicine (G.C., N.B.-P.), Pozzuoli, Naples, Italy; Department of Pediatrics and Rare Disorders (R.S.), Wroclaw Medical University, Poland; Illumina Inc (A.M., R.T.), San Diego, CA; Division of Pediatric Genetics (D.B.), Department of Genetics, Medical College of Wisconsin, Milwaukee; Department of Clinical Genetics (I.L.), Erasmus MC, University Medical Center Rotterdam; Department of Neurology (R.F.N.), Eramus MC, Medical Center Rotterdam; and Amphia Hospital (C.A.-T.), Breda, the Netherlands
| | - Alka Malhotra
- From the Dr. John T. Macdonald Foundation (M.F.D., A.P.R., S.Z.), Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami, Miller School of Medicine, FL; Department of Neurology (M.F.D.), Medical Faculty, RWTH Aachen University Hospital, Aachen, Germany; Department of Neurology (S.S., S.M.), Boston Children's Hospital, Harvard Medical School, MA; Department of Translational Medicine (G.C., N.B.-P.), Federico II University; Telethon Institute of Genetics and Medicine (G.C., N.B.-P.), Pozzuoli, Naples, Italy; Department of Pediatrics and Rare Disorders (R.S.), Wroclaw Medical University, Poland; Illumina Inc (A.M., R.T.), San Diego, CA; Division of Pediatric Genetics (D.B.), Department of Genetics, Medical College of Wisconsin, Milwaukee; Department of Clinical Genetics (I.L.), Erasmus MC, University Medical Center Rotterdam; Department of Neurology (R.F.N.), Eramus MC, Medical Center Rotterdam; and Amphia Hospital (C.A.-T.), Breda, the Netherlands
| | - Donald Basel
- From the Dr. John T. Macdonald Foundation (M.F.D., A.P.R., S.Z.), Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami, Miller School of Medicine, FL; Department of Neurology (M.F.D.), Medical Faculty, RWTH Aachen University Hospital, Aachen, Germany; Department of Neurology (S.S., S.M.), Boston Children's Hospital, Harvard Medical School, MA; Department of Translational Medicine (G.C., N.B.-P.), Federico II University; Telethon Institute of Genetics and Medicine (G.C., N.B.-P.), Pozzuoli, Naples, Italy; Department of Pediatrics and Rare Disorders (R.S.), Wroclaw Medical University, Poland; Illumina Inc (A.M., R.T.), San Diego, CA; Division of Pediatric Genetics (D.B.), Department of Genetics, Medical College of Wisconsin, Milwaukee; Department of Clinical Genetics (I.L.), Erasmus MC, University Medical Center Rotterdam; Department of Neurology (R.F.N.), Eramus MC, Medical Center Rotterdam; and Amphia Hospital (C.A.-T.), Breda, the Netherlands
| | - Ingrid van de Laar
- From the Dr. John T. Macdonald Foundation (M.F.D., A.P.R., S.Z.), Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami, Miller School of Medicine, FL; Department of Neurology (M.F.D.), Medical Faculty, RWTH Aachen University Hospital, Aachen, Germany; Department of Neurology (S.S., S.M.), Boston Children's Hospital, Harvard Medical School, MA; Department of Translational Medicine (G.C., N.B.-P.), Federico II University; Telethon Institute of Genetics and Medicine (G.C., N.B.-P.), Pozzuoli, Naples, Italy; Department of Pediatrics and Rare Disorders (R.S.), Wroclaw Medical University, Poland; Illumina Inc (A.M., R.T.), San Diego, CA; Division of Pediatric Genetics (D.B.), Department of Genetics, Medical College of Wisconsin, Milwaukee; Department of Clinical Genetics (I.L.), Erasmus MC, University Medical Center Rotterdam; Department of Neurology (R.F.N.), Eramus MC, Medical Center Rotterdam; and Amphia Hospital (C.A.-T.), Breda, the Netherlands
| | - Rinze Frederik Neuteboom
- From the Dr. John T. Macdonald Foundation (M.F.D., A.P.R., S.Z.), Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami, Miller School of Medicine, FL; Department of Neurology (M.F.D.), Medical Faculty, RWTH Aachen University Hospital, Aachen, Germany; Department of Neurology (S.S., S.M.), Boston Children's Hospital, Harvard Medical School, MA; Department of Translational Medicine (G.C., N.B.-P.), Federico II University; Telethon Institute of Genetics and Medicine (G.C., N.B.-P.), Pozzuoli, Naples, Italy; Department of Pediatrics and Rare Disorders (R.S.), Wroclaw Medical University, Poland; Illumina Inc (A.M., R.T.), San Diego, CA; Division of Pediatric Genetics (D.B.), Department of Genetics, Medical College of Wisconsin, Milwaukee; Department of Clinical Genetics (I.L.), Erasmus MC, University Medical Center Rotterdam; Department of Neurology (R.F.N.), Eramus MC, Medical Center Rotterdam; and Amphia Hospital (C.A.-T.), Breda, the Netherlands
| | - Coranne Aarts-Tesselaar
- From the Dr. John T. Macdonald Foundation (M.F.D., A.P.R., S.Z.), Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami, Miller School of Medicine, FL; Department of Neurology (M.F.D.), Medical Faculty, RWTH Aachen University Hospital, Aachen, Germany; Department of Neurology (S.S., S.M.), Boston Children's Hospital, Harvard Medical School, MA; Department of Translational Medicine (G.C., N.B.-P.), Federico II University; Telethon Institute of Genetics and Medicine (G.C., N.B.-P.), Pozzuoli, Naples, Italy; Department of Pediatrics and Rare Disorders (R.S.), Wroclaw Medical University, Poland; Illumina Inc (A.M., R.T.), San Diego, CA; Division of Pediatric Genetics (D.B.), Department of Genetics, Medical College of Wisconsin, Milwaukee; Department of Clinical Genetics (I.L.), Erasmus MC, University Medical Center Rotterdam; Department of Neurology (R.F.N.), Eramus MC, Medical Center Rotterdam; and Amphia Hospital (C.A.-T.), Breda, the Netherlands
| | - Sonal Mahida
- From the Dr. John T. Macdonald Foundation (M.F.D., A.P.R., S.Z.), Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami, Miller School of Medicine, FL; Department of Neurology (M.F.D.), Medical Faculty, RWTH Aachen University Hospital, Aachen, Germany; Department of Neurology (S.S., S.M.), Boston Children's Hospital, Harvard Medical School, MA; Department of Translational Medicine (G.C., N.B.-P.), Federico II University; Telethon Institute of Genetics and Medicine (G.C., N.B.-P.), Pozzuoli, Naples, Italy; Department of Pediatrics and Rare Disorders (R.S.), Wroclaw Medical University, Poland; Illumina Inc (A.M., R.T.), San Diego, CA; Division of Pediatric Genetics (D.B.), Department of Genetics, Medical College of Wisconsin, Milwaukee; Department of Clinical Genetics (I.L.), Erasmus MC, University Medical Center Rotterdam; Department of Neurology (R.F.N.), Eramus MC, Medical Center Rotterdam; and Amphia Hospital (C.A.-T.), Breda, the Netherlands
| | - Nicola Brunetti-Pierri
- From the Dr. John T. Macdonald Foundation (M.F.D., A.P.R., S.Z.), Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami, Miller School of Medicine, FL; Department of Neurology (M.F.D.), Medical Faculty, RWTH Aachen University Hospital, Aachen, Germany; Department of Neurology (S.S., S.M.), Boston Children's Hospital, Harvard Medical School, MA; Department of Translational Medicine (G.C., N.B.-P.), Federico II University; Telethon Institute of Genetics and Medicine (G.C., N.B.-P.), Pozzuoli, Naples, Italy; Department of Pediatrics and Rare Disorders (R.S.), Wroclaw Medical University, Poland; Illumina Inc (A.M., R.T.), San Diego, CA; Division of Pediatric Genetics (D.B.), Department of Genetics, Medical College of Wisconsin, Milwaukee; Department of Clinical Genetics (I.L.), Erasmus MC, University Medical Center Rotterdam; Department of Neurology (R.F.N.), Eramus MC, Medical Center Rotterdam; and Amphia Hospital (C.A.-T.), Breda, the Netherlands
| | - Ryan J Taft
- From the Dr. John T. Macdonald Foundation (M.F.D., A.P.R., S.Z.), Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami, Miller School of Medicine, FL; Department of Neurology (M.F.D.), Medical Faculty, RWTH Aachen University Hospital, Aachen, Germany; Department of Neurology (S.S., S.M.), Boston Children's Hospital, Harvard Medical School, MA; Department of Translational Medicine (G.C., N.B.-P.), Federico II University; Telethon Institute of Genetics and Medicine (G.C., N.B.-P.), Pozzuoli, Naples, Italy; Department of Pediatrics and Rare Disorders (R.S.), Wroclaw Medical University, Poland; Illumina Inc (A.M., R.T.), San Diego, CA; Division of Pediatric Genetics (D.B.), Department of Genetics, Medical College of Wisconsin, Milwaukee; Department of Clinical Genetics (I.L.), Erasmus MC, University Medical Center Rotterdam; Department of Neurology (R.F.N.), Eramus MC, Medical Center Rotterdam; and Amphia Hospital (C.A.-T.), Breda, the Netherlands
| | - Stephan Züchner
- From the Dr. John T. Macdonald Foundation (M.F.D., A.P.R., S.Z.), Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami, Miller School of Medicine, FL; Department of Neurology (M.F.D.), Medical Faculty, RWTH Aachen University Hospital, Aachen, Germany; Department of Neurology (S.S., S.M.), Boston Children's Hospital, Harvard Medical School, MA; Department of Translational Medicine (G.C., N.B.-P.), Federico II University; Telethon Institute of Genetics and Medicine (G.C., N.B.-P.), Pozzuoli, Naples, Italy; Department of Pediatrics and Rare Disorders (R.S.), Wroclaw Medical University, Poland; Illumina Inc (A.M., R.T.), San Diego, CA; Division of Pediatric Genetics (D.B.), Department of Genetics, Medical College of Wisconsin, Milwaukee; Department of Clinical Genetics (I.L.), Erasmus MC, University Medical Center Rotterdam; Department of Neurology (R.F.N.), Eramus MC, Medical Center Rotterdam; and Amphia Hospital (C.A.-T.), Breda, the Netherlands.
| |
Collapse
|
7
|
Fedosova NU, Habeck M, Nissen P. Structure and Function of Na,K-ATPase-The Sodium-Potassium Pump. Compr Physiol 2021; 12:2659-2679. [PMID: 34964112 DOI: 10.1002/cphy.c200018] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Na,K-ATPase is an ubiquitous enzyme actively transporting Na-ions out of the cell in exchange for K-ions, thereby maintaining their concentration gradients across the cell membrane. Since its discovery more than six decades ago the Na-pump has been studied extensively and its vital physiological role in essentially every cell has been established. This article aims at providing an overview of well-established biochemical properties with a focus on Na,K-ATPase isoforms, its transport mechanism and principle conformations, inhibitors, and insights gained from crystal structures. © 2021 American Physiological Society. Compr Physiol 11:1-21, 2021.
Collapse
Affiliation(s)
| | - Michael Habeck
- Department of Molecular Biology and Genetics, Danish Research Institute of Translational Neuroscience - DANDRITE, Nordic EMBL Partnership for Molecular Medicine, Aarhus University, Aarhus, Denmark
| | - Poul Nissen
- Department of Molecular Biology and Genetics, Danish Research Institute of Translational Neuroscience - DANDRITE, Nordic EMBL Partnership for Molecular Medicine, Aarhus University, Aarhus, Denmark
| |
Collapse
|
8
|
Jiao S, Johnson K, Moreno C, Yano S, Holmgren M. Comparative description of the mRNA expression profile of Na + /K + -ATPase isoforms in adult mouse nervous system. J Comp Neurol 2021; 530:627-647. [PMID: 34415061 PMCID: PMC8716420 DOI: 10.1002/cne.25234] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2021] [Revised: 06/16/2021] [Accepted: 08/16/2021] [Indexed: 11/09/2022]
Abstract
Mutations in genes encoding Na+ /K+ -ATPase α1, α2, and α3 subunits cause a wide range of disabling neurological disorders, and dysfunction of Na+ /K+ -ATPase may contribute to neuronal injury in stroke and dementia. To better understand the pathogenesis of these diseases, it is important to determine the expression patterns of the different Na+ /K+ -ATPase subunits within the brain and among specific cell types. Using two available scRNA-Seq databases from the adult mouse nervous system, we examined the mRNA expression patterns of the different isoforms of the Na+ /K+ -ATPase α, β and Fxyd subunits at the single-cell level among brain regions and various neuronal populations. We subsequently identified specific types of neurons enriched with transcripts for α1 and α3 isoforms and elaborated how α3-expressing neuronal populations govern cerebellar neuronal circuits. We further analyzed the co-expression network for α1 and α3 isoforms, highlighting the genes that positively correlated with α1 and α3 expression. The top 10 genes for α1 were Chn2, Hpcal1, Nrgn, Neurod1, Selm, Kcnc1, Snrk, Snap25, Ckb and Ccndbp1 and for α3 were Sorcs3, Eml5, Neurod2, Ckb, Tbc1d4, Ptprz1, Pvrl1, Kirrel3, Pvalb, and Asic2.
Collapse
Affiliation(s)
- Song Jiao
- Molecular Neurophysiology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA
| | - Kory Johnson
- Bioinformatics Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA
| | - Cristina Moreno
- Molecular Neurophysiology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA
| | - Sho Yano
- Molecular Neurophysiology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA
| | - Miguel Holmgren
- Molecular Neurophysiology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA
| |
Collapse
|
9
|
Argente-Escrig H, Frasquet M, Vázquez-Costa JF, Millet-Sancho E, Pitarch I, Tomás-Vila M, Espinós C, Lupo V, Sevilla T. Pediatric inherited peripheral neuropathy: a prospective study at a Spanish referral center. Ann Clin Transl Neurol 2021; 8:1809-1816. [PMID: 34323022 PMCID: PMC8419398 DOI: 10.1002/acn3.51432] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2021] [Revised: 07/01/2021] [Accepted: 07/02/2021] [Indexed: 11/16/2022] Open
Abstract
Background Single‐center clinical series provide important information on genetic distribution that can guide genetic testing. However, there are few such studies on pediatric populations with inherited peripheral neuropathies (IPNs). Methods Thorough genetic testing was performed on IPN patients under 20 years of age from a geographically well‐defined Mediterranean area (Valencian Community, Spain), annually assessed with the Charcot–Marie–Tooth disease Pediatric Scale (CMTPedS). Results From 86 families with IPNs, 99 patients (59 males) were identified, 85 with sensorimotor neuropathy or CMT (2/3 demyelinating form) and 14 with distal hereditary motor neuropathy (dHMN). Genetic diagnosis was achieved in 79.5% families, with a similar mutation detection rate in the demyelinating (88.7%) and axonal (89.5%) forms, significantly higher than in the dHMN families (27.3%). CMT1A was the most common subtype, followed by those carrying heterozygous mutations in either the GDAP1 or GJB1 genes. Mutations in 15 other genes were identified, including a new pathogenic variant in the ATP1A gene. The CMTPedS detected significant disease progression in all genetic subtypes of CMT, at a rate of 1.84 (±3.7) over 1 year (p < 0.0005, n = 62) and a 2‐year rate of 3.6 (±4.4: p < 0.0005, n = 45). Significant disease worsening was also detected for CMT1A over 1 (1.7 ± 3.6, p < 0.05) and 2 years (4.2 ± 4.3, p < 0.0005). Conclusions This study highlights the unique spectrum of IPN gene frequencies among pediatric patients in this specific geographic region, identifying the CMTPedS as a sensitive tool to detect significant disease worsening over 1 year that could help optimize the design of clinical trials.
Collapse
Affiliation(s)
- Herminia Argente-Escrig
- Neuromuscular & Ataxias Research Group, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.,Neuromuscular Diseases Unit, Department of Neurology, Hospital Universitari i Politècnic La Fe, Valencia, Spain.,Centre for Biomedical Network Research on Rare Diseases-CIBERER, Valencia, Spain.,Rare Diseases Joint Unit IIS La Fe - CIPF, Valencia, Spain
| | - Marina Frasquet
- Neuromuscular & Ataxias Research Group, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.,Neuromuscular Diseases Unit, Department of Neurology, Hospital Universitari i Politècnic La Fe, Valencia, Spain.,Centre for Biomedical Network Research on Rare Diseases-CIBERER, Valencia, Spain.,Rare Diseases Joint Unit IIS La Fe - CIPF, Valencia, Spain
| | - Juan Francisco Vázquez-Costa
- Neuromuscular & Ataxias Research Group, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.,Neuromuscular Diseases Unit, Department of Neurology, Hospital Universitari i Politècnic La Fe, Valencia, Spain.,Centre for Biomedical Network Research on Rare Diseases-CIBERER, Valencia, Spain.,Rare Diseases Joint Unit IIS La Fe - CIPF, Valencia, Spain
| | - Elvira Millet-Sancho
- Rare Diseases Joint Unit IIS La Fe - CIPF, Valencia, Spain.,Department of Clinical Neurophysiology, Hospital Universitari i Politècnic La Fe, Valencia, Spain
| | - Inmaculada Pitarch
- Department of Pediatrics, Neuropediatrics Unit, Hospital Universitari i Politècnic La Fe, Valencia, Spain
| | - Miguel Tomás-Vila
- Department of Pediatrics, Neuropediatrics Unit, Hospital Universitari i Politècnic La Fe, Valencia, Spain
| | - Carmen Espinós
- Rare Diseases Joint Unit IIS La Fe - CIPF, Valencia, Spain.,Unit of Genetics and Genomics of Neuromuscular and Neurodegenerative Disorders, Centro de Investigación Príncipe Felipe (CIPF), Valencia, Spain
| | - Vincenzo Lupo
- Rare Diseases Joint Unit IIS La Fe - CIPF, Valencia, Spain.,Unit of Genetics and Genomics of Neuromuscular and Neurodegenerative Disorders, Centro de Investigación Príncipe Felipe (CIPF), Valencia, Spain
| | - Teresa Sevilla
- Neuromuscular & Ataxias Research Group, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.,Neuromuscular Diseases Unit, Department of Neurology, Hospital Universitari i Politècnic La Fe, Valencia, Spain.,Centre for Biomedical Network Research on Rare Diseases-CIBERER, Valencia, Spain.,Rare Diseases Joint Unit IIS La Fe - CIPF, Valencia, Spain.,Department of Medicine, University of Valencia School of Medicine, Valencia, Spain
| |
Collapse
|
10
|
Biondo ED, Spontarelli K, Ababioh G, Méndez L, Artigas P. Diseases caused by mutations in the Na +/K + pump α1 gene ATP1A1. Am J Physiol Cell Physiol 2021; 321:C394-C408. [PMID: 34232746 DOI: 10.1152/ajpcell.00059.2021] [Citation(s) in RCA: 22] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Human cell survival requires function of the Na+/K+ pump; the heteromeric protein that hydrolyzes ATP to extrude Na+ and import K+ across the plasmalemma, thereby building and maintaining these ions' electrochemical gradients. Numerous dominant diseases caused by mutations in genes encoding for Na+/K+ pump catalytic (α) subunit isoforms highlight the importance of this protein. Here, we review literature describing disorders caused by missense mutations in ATP1A1, the gene encoding the ubiquitously expressed α1 isoform of the Na+/K+ pump. These various maladies include primary aldosteronism with secondary hypertension, an endocrine syndrome, Charcot-Marie-Tooth disease, a peripheral neuropathy, complex spastic paraplegia, another neuromuscular disorder, as well as hypomagnesemia accompanied by seizures and cognitive delay, a condition affecting the renal and central nervous systems. This article focuses on observed commonalities among these mutations' functional effects, as well as on the special characteristics that enable each particular mutation to exclusively affect a certain system, without affecting others. In this respect, it is clear how somatic mutations localized to adrenal adenomas increase aldosterone production without compromising other systems. However, it remains largely unknown how and why some but not all de novo germline or familial mutations (where the mutant must be expressed in numerous tissues) produce a specific disease and not the other diseases. We propose hypotheses to explain this observation and the approaches that we think will drive future research on these debilitating disorders to develop novel patient-specific treatments by combining the use of heterologous protein-expression systems, patient-derived pluripotent cells, and gene-edited cell and mouse models.
Collapse
Affiliation(s)
- Elisa D Biondo
- Department of Cell Physiology and Molecular Biophysics, Center for Membrane Protein Research, Texas Tech University Health Sciences Center, Lubbock, Texas
| | - Kerri Spontarelli
- Department of Cell Physiology and Molecular Biophysics, Center for Membrane Protein Research, Texas Tech University Health Sciences Center, Lubbock, Texas
| | - Giovanna Ababioh
- Department of Cell Physiology and Molecular Biophysics, Center for Membrane Protein Research, Texas Tech University Health Sciences Center, Lubbock, Texas
| | - Lois Méndez
- Department of Cell Physiology and Molecular Biophysics, Center for Membrane Protein Research, Texas Tech University Health Sciences Center, Lubbock, Texas
| | - Pablo Artigas
- Department of Cell Physiology and Molecular Biophysics, Center for Membrane Protein Research, Texas Tech University Health Sciences Center, Lubbock, Texas
| |
Collapse
|
11
|
Düsterhöft S, Kahveci-Türköz S, Wozniak J, Seifert A, Kasparek P, Ohm H, Liu S, Kopkanova J, Lokau J, Garbers C, Preisinger C, Sedlacek R, Freeman M, Ludwig A. The iRhom homology domain is indispensable for ADAM17-mediated TNFα and EGF receptor ligand release. Cell Mol Life Sci 2021; 78:5015-5040. [PMID: 33950315 PMCID: PMC8233286 DOI: 10.1007/s00018-021-03845-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2020] [Revised: 03/29/2021] [Accepted: 04/23/2021] [Indexed: 12/23/2022]
Abstract
Membrane-tethered signalling proteins such as TNFα and many EGF receptor ligands undergo shedding by the metalloproteinase ADAM17 to get released. The pseudoproteases iRhom1 and iRhom2 are important for the transport, maturation and activity of ADAM17. Yet, the structural and functional requirements to promote the transport of the iRhom-ADAM17 complex have not yet been thoroughly investigated. Utilising in silico and in vitro methods, we here map the conserved iRhom homology domain (IRHD) and provide first insights into its structure and function. By focusing on iRhom2, we identified different structural and functional factors within the IRHD. We found that the structural integrity of the IRHD is a key factor for ADAM17 binding. In addition, we identified a highly conserved motif within an unstructured region of the IRHD, that, when mutated, restricts the transport of the iRhom-ADAM17 complex through the secretory pathway in in vitro, ex vivo and in vivo systems and also increases the half-life of iRhom2 and ADAM17. Furthermore, the disruption of this IRHD motif was also reflected by changes in the yet undescribed interaction profile of iRhom2 with proteins involved in intracellular vesicle transport. Overall, we provide the first insights into the forward trafficking of iRhoms which is critical for TNFα and EGF receptor signalling.
Collapse
Affiliation(s)
- Stefan Düsterhöft
- Institute of Molecular Pharmacology, Medical Faculty, RWTH Aachen University, Wendlingweg 2, 52074, Aachen, Germany.
| | - Selcan Kahveci-Türköz
- Institute of Molecular Pharmacology, Medical Faculty, RWTH Aachen University, Wendlingweg 2, 52074, Aachen, Germany
| | - Justyna Wozniak
- Institute of Molecular Pharmacology, Medical Faculty, RWTH Aachen University, Wendlingweg 2, 52074, Aachen, Germany
| | - Anke Seifert
- Institute of Molecular Pharmacology, Medical Faculty, RWTH Aachen University, Wendlingweg 2, 52074, Aachen, Germany
| | - Petr Kasparek
- Czech Centre for Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic
| | - Henrike Ohm
- Institute of Molecular Pharmacology, Medical Faculty, RWTH Aachen University, Wendlingweg 2, 52074, Aachen, Germany
| | - Shixin Liu
- Institute of Molecular Pharmacology, Medical Faculty, RWTH Aachen University, Wendlingweg 2, 52074, Aachen, Germany
| | - Jana Kopkanova
- Czech Centre for Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic
| | - Juliane Lokau
- Department of Pathology, Medical Faculty, Otto Von Guericke University Magdeburg, Magdeburg, Germany
| | - Christoph Garbers
- Department of Pathology, Medical Faculty, Otto Von Guericke University Magdeburg, Magdeburg, Germany
| | | | - Radislav Sedlacek
- Czech Centre for Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic
| | - Matthew Freeman
- Sir William Dunn School of Pathology, University of Oxford, Oxford, UK
| | - Andreas Ludwig
- Institute of Molecular Pharmacology, Medical Faculty, RWTH Aachen University, Wendlingweg 2, 52074, Aachen, Germany
| |
Collapse
|
12
|
Lin Z, Li J, Ji T, Wu Y, Gao K, Jiang Y. ATP1A1 de novo Mutation-Related Disorders: Clinical and Genetic Features. Front Pediatr 2021; 9:657256. [PMID: 33968856 PMCID: PMC8098805 DOI: 10.3389/fped.2021.657256] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/22/2021] [Accepted: 03/25/2021] [Indexed: 02/03/2023] Open
Abstract
Background: ATP1A1 encodes an α1 isoform of Na+/K+-ATPase, which is expressed abundantly in kidneys and central nervous system. ATP1A1 variants may cause Na+/K+-ATPase loss of function and lead to a wide spectrum of phenotypes. This study aims to summarize the clinical and genetic features of ATP1A1 de novo mutation-related disorders and explore the potential correlations between phenotypes and genotypes. Methods: We analyzed two new cases harboring novel de novo ATP1A1 variants and reviewed all reported cases. Results: Both our probands had developmental delay, patient 1 accompanied with sleep disorders, irritability, and patient 2 with refractory seizures. They each had a novel de novo heterozygous missense variant, c.2797G>A[p.Asp933Asn] (NM_000701) and c.2590G>A[p.Gly864Arg] (NM_000701) respectively. Four patients with de novo ATP1A1 variants have been reported in two previous papers. Among them, three patients had refractory seizures and one patient had complex hereditary spastic paraplegia (HSP). Therefore, all six patients had developmental delay, and four of them had epilepsy. All variants located in the transmembrane regions M3, M4, M7, and M8 of ATP1A1 protein. Four patients with mutations in M3 and M7 had more severe phenotypes, including developmental delay and epileptic encephalopathy, three of them with hypomagnesemia, whereas two patients with mutations in M4 and M8 had milder phenotypes, only with mild developmental delay, without seizures or hypomagnesemia. Correcting hypomagnesemia had not controlled those seizures. Conclusions: Two novel de novo ATP1A1 variants identified in two patients here enriched the genotypic and phenotypic spectrum of ATP1A1 mutation-related disorder. Our findings suggest that hypomagnesemia in this disorder might relate to more severe phenotype and indicate more severe Na+/K+-ATPase dysfunction. Variations in M3 and M7 transmembrane regions were related to more severe phenotype than those in M4 and M8, which suggested that variations in M3 and M7 might cause more severe ATP1A1 functional defect.
Collapse
Affiliation(s)
- Zehong Lin
- Department of Pediatrics, Peking University First Hospital, Beijing, China
| | - Jinliang Li
- Department of Pediatrics, Peking University First Hospital, Beijing, China
| | - Taoyun Ji
- Department of Pediatrics, Peking University First Hospital, Beijing, China
| | - Ye Wu
- Department of Pediatrics, Peking University First Hospital, Beijing, China
| | - Kai Gao
- Department of Pediatrics, Peking University First Hospital, Beijing, China
| | - Yuwu Jiang
- Department of Pediatrics, Peking University First Hospital, Beijing, China
| |
Collapse
|